Getz Pharma and Tabba Heart Institute, in order to address the issue of the rising health burden of ASCVD in Pakistan, are entering into a Joint Venture Agreement for the largest, first-of-its-kind, longitudinal cohort study on Atherosclerotic Risk Assessment in Pakistani Population. This study aims to recruit healthy volunteers aged 30 years or older, from selected urban and rural areas of Pakistan, who are asymptomatic and have no cardiovascular disease. This would allow for assessing the participants’ risk factor profiles and follow them up for at least 10 years to document the incidence of ASCVD.
Khalid Mahmood, Managing Director and CEO Getz Pharma Pvt. Ltd and Dr. Bashir Hanif, Executive and Medical Director, Tabba Heart Institute signed a joint MoU to conduct a first of its kind extensive research cardiovascular risk management research in Pakistan (L – R) Dr. Khurram Hussein, Director Commercial and Human Resources, Getz Pharma Pvt. Ltd, Khalid Mahmood, Managing Director and CEO, Getz Pharma, Dr. Bashir Hanif, Executive and Medical Director, Tabba Heart Institute
Pakistan is the second-most populous country in South Asia, but most of the data on the prevalence of ASCVD from South Asian regions is derived from India. As a result, the Pakistani population is highly underrepresented in global research as there is currently no comprehensive database on the native Pakistani population to assess the likelihood of developing ASCVD. Due to this high burden of disease, there is an urgent need for primary prevention and early screening for ASCVD in Pakistan.
About one-fourth of the world’s population, living in the South Asian region, are at an increased risk of atherosclerotic cardiovascular diseases (ASCVD). Although Western countries have made significant progress in reducing the global health burden of ASCVD, the prevalence of the disease continues to rise in South Asian countries, and ASCVD remains a leading cause of death.
Research shows that South Asians tend to have a higher likelihood of developing risk factors leading to ASCVD, develop cardiovascular events at an earlier age, as well as have higher mortality compared to White populations, according to multiple population-based studies. This higher incidence of ASCVD amongst South Asians can be attributed to various biological and lifestyle-related factors. However, most of the studies conducted so far have focused on migrant South Asian populations residing in the West, causing a large gap in the data for Pakistan-specific prevalence of ASCVD.
Khalid Mahmood, Managing Director and CEO, Getz Pharma made his opening remarks at the MoU signing between Tabba Heart Institute and Getz Pharma held on April 28, 2021
During the MoU signing ceremony, Khalid Mahmood shared his opening remarks for this initiative, “As a pharmaceutical company, research is something we all depend on to develop medicines. Hence, investing in primary healthcare is crucial, especially for a country like Pakistan which spends a minuscule percentage of its GDP on healthcare, much less than what is required for it to spend, as per WHO recommendations. There is a need for developing nations to invest more in primary health compared to tertiary healthcare and prevent diseases before they become an added burden on our hospitals.”
Dr. Bashir Hanif, Executive and Medical Director, Tabba Heart Institute speaking on the MoU signing ceremony
Dr. Bashir Hanif added, “I can’t thank Getz Pharma enough for supporting this research. This is going to be a landmark study, which no one else has done in Pakistan before. It will help shed light on the prevalence of cardiovascular diseases amongst the younger, native Pakistani population under 40 years of age. There is a long way to go, but we hope that we will be able to accomplish this task via dedication and teamwork.”
So far, Getz Pharma has contributed 0.5 million USD to this longitudinal study. In addition, Getz Pharma and Tabba Health Institute will collectively raise a further 1.5 million USD over the course of the 10-year initiative.
Department heads from Getz Pharma stand with the Executive and Medical Director and Chief Operating Officer of Tabba Heart Institute along with their marketing and research team representatives
The findings from a study of this scale can provide groundbreaking results in the long run, as it would help in informing future health policy targeting the native Pakistani population, and it would also allow early interventions for patients with risk of ASCVD from a younger age. Getz Pharma and Tabba Heart Institute are proud to lead an initiative of this scale with the aim to contribute to the growing research database in Pakistan and promote early screening and prevention for cardiovascular diseases in the country.
You are about to be redirected to an online retailer’s website. Getz Pharma is not liable for any data exchange on the new website
You will be redirected in 3secs
Disclaimer: "This message (including attachment) is intended solely for the use of the individual or entity whom it is addressed and may contain information that is confidential or privileged. If you are not the intended recipient of this message, you are hereby notified that any use, dissemination, distribution or reproduction of this message is prohibited and that, you must not take any action in reliance on it. E-mail transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrived incomplete or contain viruses; therefore Getz Pharma (Private) Limited cannot accept legal responsibility for the contents of this message. If you have received this communication in error, please notify the sender or Getz Pharma (Private) Limited at [email protected] immediately and destroy the original message."
Close
